Dianthus Therapeutics, Inc. DNTH

US Biotechnology

$89.00 ▼ -1.11% ($-1.00)

Open $89.93

Prev Close $90.00

Day Range $87.95 – $90.49

52W Range $34.29 – $117.88

Market Cap $5.07B

Beta 2.06

EPS (TTM) $-4.15

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-06-21
Shares Out.	55,930,000
Website	dianthustx.com/ ↗
Phone	13026587581
Employees	92
Revenue	$1.2M
Gross Profit	$1.2M
Net Income	-$46.6M
Free Cash Flow	-$175.9M
Total Assets	$1.28B
Total Liabilities	$34.8M
Equity	$1.24B

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Dianthus Therapeutics, Inc. is a publicly traded company under the ticker symbol DNTH on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.